Computed Tomography Coronary Angiography for the Prevention of Myocardial Infarction (The SCOT-HEART 2 Trial)
Launched by UNIVERSITY OF EDINBURGH · Apr 17, 2019
Trial Information
Current as of May 13, 2025
Recruiting
Keywords
ClinConnect Summary
The SCOT-HEART 2 Trial is studying whether a special type of imaging called computed tomography coronary angiography (CTCA) can help prevent serious heart problems, like heart attacks, in people at risk for cardiovascular diseases. Researchers believe that using this advanced imaging technique to guide treatment will be more effective than the current standard method, which mainly relies on assessing cardiovascular risk factors.
To participate in this trial, individuals aged 40 to 70 who live in Scotland and have certain risk factors for heart disease, such as high blood pressure, high cholesterol, diabetes, or a family history of heart problems, may be eligible. Participants will undergo a CT scan to get detailed images of their heart and blood vessels, which will help doctors tailor their preventive care. It’s important to note that individuals with existing heart disease or certain serious conditions may not be suitable for this trial. Overall, this study aims to improve heart health and reduce the risk of heart-related events in those who need it most.
Gender
ALL
Eligibility criteria
- • INCLUSION CRITERIA
- • ≥40 and ≤70 years of age
- • Resident in Scotland and have a Community Health Index (CHI) number
- * One or more of the following risk factors:
- • \>60 years of age
- • Current or recent (within 12 months) smoker
- • Clinical diagnosis of hypertension
- • Known hypercholesterolaemia or total cholesterol \>6.0 mmol/L or receiving statin therapy
- • Diabetes mellitus
- • Rheumatoid arthritis
- • Systemic lupus erythematosus (SLE)
- • Family history of premature cardiovascular disease (first degree relative with atherosclerotic cardiovascular disease below 60 years)
- • Chronic kidney disease stage 3 (estimate glomerular filtration rate 30-59 mL/min/1.73 m2).
- • EXCLUSION CRITERIA
- • Inability to undergo CTCA
- • Known coronary heart disease or other major atherosclerotic cardiovascular disease
- • Prior invasive or non-invasive coronary angiography within the last 5 years
- • Chronic kidney disease stage ≥4 (estimate glomerular filtration rate \<30 mL/min/1.73 m2)
- • Known homozygous familial hypercholesterolaemia or other serious inherited disorders of lipid metabolism requiring statin therapy
- • Intolerance of all statins
- • Statin therapy for \>2 years.
- • Previous coronary artery imaging completed specifically for cardiovascular risk assessment with a result of \>10 AU.
About University Of Edinburgh
The University of Edinburgh, a prestigious institution renowned for its commitment to research excellence and innovation, serves as a leading clinical trial sponsor dedicated to advancing healthcare through rigorous scientific inquiry. With a strong emphasis on multidisciplinary collaboration, the university facilitates cutting-edge clinical studies that aim to explore novel therapies and improve patient outcomes. Leveraging its extensive network of researchers, healthcare professionals, and state-of-the-art facilities, the University of Edinburgh is at the forefront of translating scientific discoveries into practical applications, thereby contributing significantly to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Edinburgh, , United Kingdom
Patients applied
Trial Officials
David E Newby
Principal Investigator
University of Edinburgh
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials